Overview

Innovative therapies demand extraordinary means. With an international team of renowned scientists, proven competence in clinical development, and a global network of experts and reliable partners, we differentiate our pipeline by using an indication-driven, technology-agnostic approach. As innovator for antiviral and antibacterial therapies, we target indications with high medical need today and prepare for future threats.

 

Our Pipeline – Innovative solutions for serious infectious diseases.

 

Solving the medical needs of today

Our main pipeline focus is on indications with a particularly high, current medical need, for which no efficient solutions are available. Finding these solutions is one of AiCuris’ two priorities, and we highly invest into the appropriate selection of indication and approach. Our diverse program targets both viral and bacterial areas of unmet medical need, addressing niche markets as well as big indications.

show Projects

Preparing for future threats

The global COVID -19 pandemic has taught the world that potential future infectious threats should not be underestimated. We are convinced that anti-microbial resistance (AMR) will become a significant threat to mankind in future and have actively worked on identifying new anti-bacterial agents since our inception. In 2020, we additionally launched a “Pandemic and Resistance Emergency Preparedness (PREP) program” and expanded our pipeline by targeting potential viral pandemics, including SARS-CoV-2.

show Projects

If you or your company are interested in partnering with AiCuris, please contact us.

Contact